Open AccessReduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis
Author(s) -
Kamiar Alaei,
Arash Alaei,
Davoud Mansouri
Publication year - 2002
Publication title -
eastern mediterranean health journal/eastern mediterranean health journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 47
eISSN - 1687-1634
pISSN - 1020-3397
DOI - 10.26719/2002.8.6.754
Subject(s) - medicine , chemoprophylaxis , tuberculosis , isoniazid , tuberculin , human immunodeficiency virus (hiv) , immunology , pathology
Isoniazid [INH] chemoprophylaxis has a positive impact on the development of clinical tuberculosis. Due to the increased prevalence of tuberculosis among HIV-infected individuals, we evaluated the effect of INH on the prevention of clinical tuberculosis in HIV-infected patients. We administered 300 mg of INH daily to 246 HIV-infected, tuberculin skin test-positive patients for 12 months. During 3 years of follow-up, 41 participants died and 94 were lost to follow up. Of the 111 patients followed for the 3 years, 12 developed tuberculosis which is lower than might be expected in an untreated group. INH prophylaxis appears to be an effective method to prevent clinical tuberculosis among HIV-infected, tuberculin skin test-positive patients.